ampicillin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, 6-aminopenicillanic acid derivatives	198	69-53-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ampicillin hydrate ampicillin ampicillin sodium ampicillin trihydrate ampicillin anhydrous	Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic. Molecular weight: 349.41 Formula: C16H19N3O4S CLOGP: -1.20 LIPINSKI: 0 HAC: 7 HDO: 3 TPSA: 112.73 ALOGS: -2.76 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ampicillin hydrate
ampicillin
ampicillin sodium
ampicillin trihydrate
ampicillin anhydrous

Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.

Molecular weight: 349.41
Formula: C16H19N3O4S
CLOGP: -1.20
LIPINSKI: 0
HAC: 7
HDO: 3
TPSA: 112.73
ALOGS: -2.76
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O
6	g	P
2	g	R
6	g	P

ADMET properties:

Show entries

Search:

Property	Value	Reference
EoM (Fraction excreted unchanged in urine)	88 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	62 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
S (Water solubility)	50 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
CL (Clearance)	2.80 mL/min/kg	Lombardo F, Berellini G, Obach RS
MRTD (Maximum Recommended Therapeutic Daily Dose)	166.85 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
t_half (Half-life)	1.40 hours	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.85 %	Lombardo F, Berellini G, Obach RS
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS

Showing 1 to 9 of 9 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Dec. 17, 1965	FDA	WYETH AYERST

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature delivery	697.12	16.35	248	11642	30033	63447099
Normal labour	437.61	16.35	77	11813	440	63476692
Maternal exposure during pregnancy	416.09	16.35	337	11553	219725	63257407
Delivery	378.02	16.35	80	11810	1323	63475809
Drug hypersensitivity	323.57	16.35	341	11549	310346	63166786
Type IV hypersensitivity reaction	266.06	16.35	69	11821	2829	63474303
Cross sensitivity reaction	230.49	16.35	58	11832	2104	63475028
Premature baby	203.40	16.35	92	11798	20643	63456489
Foetal exposure during pregnancy	187.94	16.35	100	11790	31862	63445270
Exposure during pregnancy	154.55	16.35	167	11723	155380	63321752

Showing 1 to 10 of 131 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Premature baby	185.27	16.07	94	9006	19539	34928292
Foetal exposure during pregnancy	134.53	16.07	97	9003	38004	34909827
Low birth weight baby	92.91	16.07	44	9056	7861	34939970
Sepsis neonatal	87.07	16.07	19	9081	257	34947574
Neonatal disorder	75.35	16.07	21	9079	809	34947022
Drug hypersensitivity	68.31	16.07	94	9006	80435	34867396
Red blood cell hyperchromic morphology	65.62	16.07	10	9090	10	34947821
Type IV hypersensitivity reaction	56.06	16.07	19	9081	1415	34946416
Cardiac septal defect	52.79	16.07	13	9087	306	34947525
Pleocytosis	50.26	16.07	14	9086	538	34947293

Showing 1 to 10 of 87 entries

Previous1 2 3 4 5…9Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Type IV hypersensitivity reaction	337.81	14.09	89	14451	3992	79725856
Cross sensitivity reaction	255.56	14.09	70	14470	3642	79726206
Drug hypersensitivity	223.03	14.09	273	14267	298643	79431205
Premature delivery	167.60	14.09	83	14457	23384	79706464
Exposure during pregnancy	166.84	14.09	142	14398	100990	79628858
Rash maculo-papular	143.13	14.09	102	14438	55976	79673872
Maternal exposure during pregnancy	125.40	14.09	139	14401	136399	79593449
Pathogen resistance	118.30	14.09	56	14484	14286	79715562
Drug reaction with eosinophilia and systemic symptoms	109.55	14.09	92	14448	64152	79665696
Enterocolitis haemorrhagic	95.65	14.09	29	14511	2165	79727683

Showing 1 to 10 of 131 entries

Previous1 2 3 4 5…14Next

FDA Adverse Event Reporting System (Pediatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Foetal exposure during pregnancy	51.47	19.92	34	835	12807	76116
Drug ineffective	45.70	19.92	53	816	999	87924
Abdominal distension	28.02	19.92	16	853	98	88825
Candida infection	25.71	19.92	14	855	77	88846
Haematochezia	23.83	19.92	9	860	16	88907
Intraventricular haemorrhage	23.40	19.92	16	853	140	88783
Pulmonary haemorrhage	21.61	19.92	21	848	315	88608
Thrombocytopenia	20.93	19.92	12	857	74	88849

Showing 1 to 8 of 8 entries

Previous1Next

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	J01CA01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Penicillins with extended spectrum
ATC	J01CA51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Penicillins with extended spectrum
ATC	J01CR01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Combinations of penicillins, incl. beta-lactamase inhibitors
ATC	S01AA19	SENSORY ORGANS OPHTHALMOLOGICALS ANTIINFECTIVES Antibiotics
CHEBI has role	CHEBI:36047	antibacterial drugs
FDA CS	M0016152	Penicillins
FDA EPC	N0000175497	Penicillin-class Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Showing 1 to 9 of 9 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Acute otitis media	indication	3110003
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Gonorrhea	indication	15628003	DOID:7551
Haemophilus Influenzae Acute Otitis Media	indication	19021002
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Acute gonococcal cervicitis	indication	20943002	DOID:10615
Acute bacterial epiglottitis	indication	21060003
Staphylococcal pneumonia	indication	22754005
Streptococcal septicemia	indication	29577008

Showing 1 to 10 of 117 entries

Previous1 2 3 4 5…12Next

🐶 Veterinary Drug Use

Show entries

Search:

Species	Use	Relation
Cats	Skin, Soft Tissue and Post-Surgical Infections caused by Escherichia coli	Indication
Cats	Skin, Soft Tissue and Post-Surgical Infections caused by Proteus mirabilis	Indication
Cats	Skin, Soft Tissue and Post-Surgical Infections caused by hemolytic streptococci	Indication
Cats	Skin, Soft Tissue and Post-Surgical Infections caused by Staphylococcus spp	Indication
Cats	Skin, Soft Tissue and Post-Surgical Infections caused by Pasteurella spp	Indication
Cats	Urinary Tract Infections caused by Proteus mirabilis	Indication
Cats	Urinary Tract Infections caused by Escherichia coli	Indication
Cats	Urinary tract infections caused by Staphylococcus species	Indication
Cats	Urinary Tract Infections caused by hemolytic streptococci	Indication
Cats	Urinary Tract Infections caused by Enterococcus spp	Indication

Showing 1 to 10 of 109 entries

Previous1 2 3 4 5…11Next

🐶 Veterinary products

Show entries

Search:

Product	Applicant	Ingredients
Amp-Equine	Zoetis Inc.	1
Ampi-Bol	Zoetis Inc.	1
Ampi-Ject	Zoetis Inc.	1
Ampi-Tab	Zoetis Inc.	1
Ampicillin Sodium	HQ Specialty Pharma Corp.	1
Ampicillin Trihydrate	HQ Specialty Pharma Corp.	1
Omnipen 250 mg	Zoetis Inc.	1
Polyflex	Boehringer lngelheim Animal Health USA Inc.	1
Princillin Injection	Zoetis Inc.	1
Princillin Injection	Zoetis Inc.	1

Showing 1 to 10 of 11 entries

Previous1 2Next

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.79	acidic
pKa2	7.67	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Angiopoietin-1 receptor	Kinase	Q02763	TIE2_HUMAN		Kd	4.09	CHEMBL
Transient receptor potential cation channel subfamily M member 4	Ion channel	Q8TD43	TRPM4_HUMAN		IC50	4.72	CHEMBL
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR			CHEMBL	CHEMBL
Penicillin-binding protein 1A	Enzyme		PBPA_CLOPE				WOMBAT-PK

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
AIC	PDB_CHEM_ID
002692	NDDF
002693	NDDF
002694	NDDF
002695	NDDF
10896	IUPHAR_LIGAND_ID
1268946000	SNOMEDCT_US
1339	INN_ID
17720	MMSL
203115	RXNORM

Showing 1 to 10 of 36 entries

Previous1 2 3 4Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9816	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9816	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9816	INJECTION, POWDER, FOR SOLUTION	1 g	INTRAMUSCULAR	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9817	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAMUSCULAR	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9818	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9818	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	13 sections
AMPICILLIN	HUMAN PRESCRIPTION DRUG LABEL	1	0404-9818	INJECTION, POWDER, FOR SOLUTION	2 g	INTRAVENOUS	ANDA	13 sections
Ampicillin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3718	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	23 sections
Ampicillin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3718	INJECTION, POWDER, FOR SOLUTION	500 mg	INTRAVENOUS	ANDA	23 sections
Ampicillin	HUMAN PRESCRIPTION DRUG LABEL	1	0409-3719	INJECTION, POWDER, FOR SOLUTION	250 mg	INTRAVENOUS	ANDA	23 sections

Showing 1 to 10 of 30 entries

Previous1 2 3Next